TTM
−$1.11
YoY change
-45.3%
5Y CAGR
—
Peak year (2012)
−$0.01
Latest annual
−$1.45
EPS (Diluted) history chart for Relmada Therapeutics (RLMD) from 2012 to 2025
Latest: −$1.45
EPS (Diluted) growth chart for Relmada Therapeutics (RLMD) from 2012 to 2025
Latest: -45.3%
EPS (Diluted) history table for Relmada Therapeutics (RLMD) from 2012 to 2025
| 2025 | −$1.45 | -45.3% | +$1.20 | ||
| 2024 | −$2.65 | -19.2% | +$0.63 | ||
| 2023 | −$3.28 | -38.1% | +$2.02 | ||
| 2022 | −$5.30 | -26.0% | +$1.86 | ||
| 2021 | −$7.16 | +87.9% | −$3.35 | ||
| 2020 | −$3.81 | +133.7% | −$2.18 | ||
| 2019 | −$1.63 | -40.5% | +$1.11 | ||
| 2018 | −$2.74 | -4.2% | +$0.12 | ||
| 2017 | −$2.86 | +37.5% | −$0.78 | ||
| 2016 | −$2.08 | +101.9% | −$1.05 | ||
| 2015 | −$1.03 | -87.7% | +$7.34 | ||
| 2014 | −$8.37 | +26387.3% | −$8.34 | ||
| 2013 | −$0.03 | +271.8% | −$0.02 | ||
| 2012 | −$0.01 | — | — |
- 2025−$1.45-45.3%
- 2024−$2.65-19.2%
- 2023−$3.28-38.1%
- 2022−$5.30-26.0%
- 2021−$7.16+87.9%
- 2020−$3.81+133.7%
- 2019−$1.63-40.5%
- 2018−$2.74-4.2%
- 2017−$2.86+37.5%
- 2016−$2.08+101.9%
- 2015−$1.03-87.7%
- 2014−$8.37+26387.3%
- 2013−$0.03+271.8%
- 2012−$0.01—
EPS (Diluted) values are taken from Relmada Therapeutics's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About EPS (Diluted) at Relmada Therapeutics (RLMD)
According to Relmada Therapeutics's latest reported financial statements, the company's current diluted EPS (TTM) is −$1.11. Diluted earnings per share (EPS) is net income divided by the diluted weighted-average shares outstanding over the period. It expresses profit on a per-share basis — the figure investors use to value an individual share — and accounts for potential dilution from options, RSUs, and convertible securities.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
As of the 2025 fiscal year, Relmada Therapeutics (RLMD) reported diluted EPS of −$1.45 – plunged 45.3% year-over-year.
Across the available history, diluted EPS reached its high of −$0.01 in 2012 and its low of −$8.37 in 2014.
Relmada Therapeutics EPS (Diluted) by Year
Relmada Therapeutics EPS (Diluted) 2025: −$1.45
Relmada Therapeutics posted diluted EPS of −$1.45 in 2025, plunged 45.3% below 2024.
Relmada Therapeutics EPS (Diluted) 2024: −$2.65
In 2024, Relmada Therapeutics reported diluted EPS of −$2.65, declined 19.2% below 2023.
Relmada Therapeutics EPS (Diluted) 2023: −$3.28
Relmada Therapeutics diluted EPS in 2023 was −$3.28, plunged 38.1% below 2022.
Relmada Therapeutics EPS (Diluted) 2022: −$5.30
2022's diluted EPS for Relmada Therapeutics came in at −$5.30, declined 26.0% below 2021.
Relmada Therapeutics EPS (Diluted) 2021: −$7.16
Relmada Therapeutics diluted EPS in 2021 was −$7.16.
See more financial history for Relmada Therapeutics (RLMD). Or calculate EPS yourself.
Sector peers by EPS (Diluted)
Healthcare peers of Relmada Therapeutics (RLMD), ranked by their latest diluted EPS
| $22.95 | |
| $14.23 | |
| $13.23 | |
| $11.03 | |
| $7.28 | |
| $6.54 | |
| $3.59 | |
| $2.37 |
- $22.95
- $14.23
- $13.23
- $11.03
- $7.28
- $6.54
- $3.59
- $2.37
Frequently asked questions
Relmada Therapeutics (RLMD) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation